Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00297648
Status:
COMPLETED
Last Update Posted:
2011-08-31
First Post:
2006-02-27
Brief Title:
Mucosal Healing Study in Crohns Disease CD
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha TNFα on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohns Disease
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MUSIC
Brief Summary:
The aim of the study will be to investigate the effect of certolizumab pegol on the intestinal mucosa in active Crohns disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT Number 2005-003977-25 | OTHER | EudraCT | None |